April Electronic Mailbags
FDA Letter- Retatrutide in Compounded Drug Products
As part of NABP’s continuing partnership with the United States Food and Drug Administration (FDA) to safeguard pharmacy practice and the pharmaceutical drug supply chain in the United States, NABP is sharing the attached letter from the FDA which details concerns of drug products containing retatrutide.
This letter clearly indicates that compounding prescription drug products with retatrutide is prohibited by all pharmacies compounding under either Section 503A or 503B of the Federal Food, Drug and Cosmetic Act FD&C Act).
Please contact the FDA Office of Compounding Quality and Compliance at compounding@fda.hhs.gov with any additional questions or specific concerns.
In addition, if you have any questions specific to NABP you can contact William “Bill” Cover, Associate Executive Director at wcover@nabp.pharmacy.
UPDATE: DEA Rulemaking Regulating Controlled Substance Prescribing via Telemedicine
The Drug Enforcement Administration and the Department of Health and Human Services are delaying the effective date of the two final rules titled “Expansion of Buprenorphine Treatment via Telemedicine Encounter” and “Continuity of Care via Telemedicine for Veterans Affairs Patients” to December 31, 2025.
This notice was published in the Federal Register on 3/24/25.
The Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications continues to allow practitioners to prescribe controlled substances via telemedicine through December 31, 2025, at which point the final rules referenced above will be effective.
NAPLEX Score Transfer Fee Adjustment
The National Association of Boards of Pharmacy® (NABP®) would like to remind the boards of pharmacy and the deans of schools and colleges of pharmacy of a fee adjustment that will be implemented on June 2, 2025.
The North American Pharmacist Licensure Examination® (NAPLEX®) score transfer fee will increase from $75 to $105 per jurisdiction.
NABP regularly reviews its examination programs to determine when adjustments are necessary to cover increases in vendor fees and operational costs. The NAPLEX score transfer fee last increased 18 years ago, in 2006.
If you have any questions, please contact the NABP Competency Assessment team via email at CompAssess@nabp.pharmacy or by phone at 847/391-4406.
Proposed Amendments to the NABP Constitution and Bylaws 121st Annual Meeting, May 13-16, 2025
The National Association of Boards of Pharmacy (NABP) Constitution and Bylaws is a carefully constructed document that has guided the Association well for its 121 years of existence. Over the course of that time, the Constitution and Bylaws have been amended by the membership when warranted.
In May of this year at the 121st NABP Annual Meeting, the NABP membership will hear proposed amendments to the NABP Constitution and Bylaws and vote on proposed amendments to the NABP Bylaws. Attached are the submitted amendments and summaries for your reference. The proposed amendments are being forwarded to you in accordance with the requirement of the Constitution and Bylaws to provide proposed amendments to the member jurisdictions at least 30 days prior to the Annual Meeting.
Please contact Lemrey “Al” Carter, Executive Director/Secretary at ExecOffice@nabp.pharmacy if you have any questions.